



# ESDP Chamonix 2009

## PROGRAMME

**Tuesday 16 June 2009**

**19h30 : WELCOME PARTY AT THE HOTEL**

**(FREE DINNER)**

-----

**Wednesday 17 June 2009**

**8h45 - Welcome address** Imti Choonara Derby - UK & Gérard Pons Paris - France

### **9h00 - SYMPOSIUM I (60 mn)**

**Challenges in immunization**

*Topic leader : Marta Granström, Karolinska Institute – Sweden*

**9h00 - 9h20 : Neonatal vaccination**

*David Goldblatt, UCL Institute of Child Health, London - U.K.*

**9h20 – 9h40 : Vaccination of prematures**

*Paul Heath, St George's, University of London – U.K.*

**9h40 – 10h00 : Vaccinating immunosuppressed patients**

*Per Ljungman, Karolinska University Hospital, Huddinge – Sweden*

### **10h00 - SYMPOSIUM II (60 mn)**

**Medicines for adolescents reproductive health**

*Topic leader : Viveca Odling, Uppsala – Sweden*

**10h00 – 10h20 : Contraceptive choices**

*Viveca Odling, Uppsala – Sweden*

**10h20 – 10h40 : Emergency contraception**

*Tanja Tyden, Uppsala - Sweden*

**10h40 – 11h00 : Medical abortion**

*Kristina Gemzell, Karolinska University Hospital, Huddinge – Sweden*

**11h00** Coffee break

**11h20 STATE OF THE ART LECTURE I (40 mn)**

**11h20 – 12h00 : Modeling and simulation for paediatric drug development**

*Jean-Louis Steimer, Novartis, Basel - Switzerland*

**12h00 - SYMPOSIUM III (60 mn)**

**Modeling and simulation for paediatric drug development**

*Topic leader : Steven Kern, Salt Lake City – U.S.A.*

**12h00 – 12h20 : An industry perspective**

*Olivier Luttringer, Novartis*

**12h20 – 12h40 : An academic training perspective**

*Steven Kern, University of Utah - U.S.A.*

**12h40 – 13h00 : A clinical network perspective**

*James C. McElroy, Queen's University, Belfast - Ireland*

**13h00 LUNCH**

**14h30 FREE COMMUNICATIONS I (90 mn)**

**16h00** Coffee break

**16h20 POSTER DISCUSSION I (60 mn)**

**17h20 STATE OF THE ART LECTURE II (40 mn)**

**17h20 – 18h00 : Ethics and methodology in children undergoing clinical studies**

*Jean-Paul Amann, College de France, Paris - France*

**18h30 – 19h30 CONCERT**

***Thomas CHIRON (Piano), Jule VORTISCH (Vocal)***

-----

## THURSDAY 18 JUNE 2009

### 8h30 STATE OF THE ART LECTURE III (40 mn)

**8h30 – 9h10 : State of the art in perinatal medicines or regulatory perspectives for drugs in pregnancy**

*Donald Mattison, NIH, Washington – U.S.A.*

### 9h10 - SYMPOSIUM IV (60 mn)

**Perinatal medicines 1 : Medicines in pregnancy**

*Topic leaders : Donald Mattison, NIH, Washington - U.S.A.*

*Marc Bardou, INSERM, Faculty of Medicine, Dijon - France*

**9h10 – 9h30 : Pharmacological impact of physiological changes in pregnancy**

*Shannon Clark, UTMB, Galveston - U.S.A.*

**9h30 – 9h50 : Pharmacodynamics & pharmacokinetics of glyburide in pregnancy**

*Mary Hebert, Washington University, Seattle - U.S.A.*

**9h50 – 10h10 : Obesity and its effects on the myometrium, including the obesity related peptides.**

*John Morrison, University College Hospital, Galway – Ireland TBC*

**10h10 Coffee break**

### 10h30 FREE COMMUNICATIONS I (60 mn)

### 11h30 SYMPOSIUM V (60 mn)

**Perinatal medicines 2 : Medicines in pregnancy**

*Topic leaders : Donald Mattison, NIH, Washington - USA*

*Marc Bardou, INSERM, Faculty of Medicine, Dijon - France*

**11h30 – 11h50 : Why tocolytics failed ? The consequence of ignoring pharmacology in pregnancy.**

*Steve Caritis, Pittsburg University, U.S.A.*

**11h50 – 12h10 : Phosphodiesterase inhibitors (I.P.D.E.) and preterm labour.**

*Céline Mehats, I.N.S.E.R.M. U767, Paris - France*

**12h10 – 12h30 : Myometrial consequences of infection/inflammation and the role of beta-3 adrenergic receptor stimulation.**

*Marc Bardou, INSERM, Faculty of Medicine, Dijon – France*

### 12h30 EXCURSION TO THE GLACIER “MER DE GLACE”

**13h00 LUNCH**

## 17h30 SYMPOSIUM VI (1h20)

### **Challenges of drug therapy for children throughout the world**

*Topic leaders: Imti Choonara – Gérard Pons*

**17h30 – 17h50 : Access to essential medicines for children**

*Sue Hill, WHO, Geneva - Switzerland*

**17h50 – 18h10 : Current issues in antimalarial drug therapy in children**

*Karen Barnes, Cape Town University - South Africa*

**18h10 – 18h30 : Ensuring children with epilepsy receive treatment worldwide**

*Hubert Barennes, PDR, Vientiane - Laos*

**18h30 – 18h50 : Drug therapy of pneumonia in the developing world**

*Shamim Qazi, WHO, Geneva- Switzerland*

**18h50 Free time**

**20h00 GALA DINNER at “LA CABANE”**

-----

**Friday 19 June 2009**

**8h30 STATE OF THE ART LECTURE IV (40 mn)**

**8h30 – 9h10 : Observational studies and level of proof**

*Yola Moride, Pharmacy Dpt, Montreal University, Quebec*

**9h10 SYMPOSIUM VII (60 mn)**

### **Pharmacoepidemiology to evaluate paediatric drugs**

*Topic leaders : Lamiae Grimaldi – Bensouda, LaSer, Paris - France*

*Martin Chalumeau, St Vincent de Paul Hospital, Paris – France*

**9h10 – 9h30 : Pharmacoepidemiologic studies to evaluate drug safety in children**

*Yola Moride, Pharmacy Dpt, Montreal University, Quebec, Canada.*

**9h30 – 9h50 : Nordic study on SSRIs and risks of congenital malformations, abortions, perinatal death and persistent pulmonary hypertension of the newborn.**

*Helle Kieler, Karolinska University Hospital, Stockholm, Sweden TBC*

**9h50 – 10h10 : A cohort to evaluate drug efficacy in children : example of prenatal corticosteroids**

*Laurence Foix-L’Helias, Epidemiological Research Unit on perinatal health, INSERM, Antoine Beclere Hospital, Paris – France*

**10h10 Coffee break**

### 10h30 SYMPOSIUM VIII (60 mn)

#### **Innovative therapeutic approaches : the example of cystic fibrosis**

*Topic leader : Franck Dufour, Cystic Fibrosis Europe, Brussels - Belgium*

#### **10h30 – 10h50 : The role of patient organization in drug development : the example of CF**

*Franck Dufour, Cystic Fibrosis Europe, Brussels - Belgium*

#### **10h50 – 11h10 : Screening of new molecules, tissue models and cystic fibrosis *in silico* model**

*Frederic Becq, Poitiers University - France*

#### **11h10 – 11h30 : Early clinical development of a new drug for CF**

**TBF**

### 11h30 FREE COMMUNICATIONS II (60 mn)

**12h30 LUNCH**

### 14h00 SYMPOSIUM IX (60 mn)

#### **Current issues in drug development of anti-epileptic drugs in children**

*Topic leader : Catherine Chiron, INSERM U663 Necker Hospital, Paris – France*

#### **14h00 – 14h20 : Anti-epileptic drug development in children : considerations for a revisited strategy**

*Catherine Chiron, INSERM U663 Necker Hospital, Paris – France*

#### **14h20 – 14h40 : Bumetanide in neonatal seizures**

*Ronit Pressler, Great Ormond Street Hospital for Children, London – U.K.*

#### **14h40 – 15h00 : Anti-epileptic drugs in animal models**

*Rima Nabbout-Massimo, Mantegazza - Italy*

**15h00 Coffee break**

### 15h20 POSTER DISCUSSION II (60 mn)

### 16h20 SYMPOSIUM X (60 mn)

#### **Current issues in drug neuroprotection in children**

*Topic leader : Pierre Gressens, INSERM, Robert Debré Hospital, Paris - France*

#### **16h20 – 16h40 : Neuronal apoptosis and neuroprotection**

*Heinrich Hagberg, Institute Reproductive & Developmental Biology, Göteborg - Sweden*

#### **16h40 – 17h00 : Neuroprotection in neonates**

*Pierre Gressens, INSERM, Robert Debré Hospital, Paris - France*

#### **17h00 – 17h20 : Neuroprotection and erythropoietin**

**TBF**

### 17h20 GENERAL ASSEMBLY

-----

## **Saturday 20 June 2009**

**8h45 FREE COMMUNICATIONS III (90 mn)**

**10h15 STATE OF THE ART LECTURE V (40 mn)**

**The EU network for the evaluation of medicinal products in children**  
*Agnès Saint-Raymond, EMEA, London – U.K.*

**10h45 Coffee break**

**11h05 SYMPOSIUM XI (60 mn)**

**Current issues in drug development of anti-cancer agents in children**  
*Topic leader : Gilles Vassal, ITCC, Paris – France*

**11h05 – 11h25 : The challenges of new drug development for children with cancer**  
*Gilles Vassal, ITCC, Paris – France*

**11h25 – 11h45 : Targeted therapies in paediatric malignancies**  
*Birgit Georger, IGR, Paris – France*

**11h45 – 12h05 : Caring for quality of cure in long term survivors**  
*Kathy Pritchard-Jones, Institute of Cancer Research, Sutton – U.K.*

**12h05 Summary of the congress and farewell address - Gérard Pons**

**12h25 LUNCH**

**14h00 End of meeting**